DNA methylome combined with chromosome cluster-oriented analysis provides an early signature for cutaneous melanoma aggressiveness

  1. Arnaud Carrier
  2. Cécile Desjobert
  3. Loic Ponger
  4. Laurence Lamant
  5. Matias Bustos
  6. Jorge Torres-Ferreira
  7. Rui Henrique
  8. Carmen Jeronimo
  9. Luisa Lanfrancone
  10. Audrey Delmas
  11. Gilles Favre
  12. Antoine Delaunay
  13. Florence Busato
  14. Dave SB Hoon
  15. Jorg Tost
  16. Chantal Etievant
  17. Joëlle Riond
  18. Paola B Arimondo  Is a corresponding author
  1. CNRS-Pierre Fabre, France
  2. CNRS UMR 7196, INSERM U1154, France
  3. UMR 1037, INSERM, Université Toulouse III Paul Sabatier, France
  4. Providence Saint John's Health Center, United States
  5. Portuguese Oncology Institute, Portugal
  6. Instituto Europeo di Oncologia, Italy
  7. Fondation Jean Dausset-CEPH, France
  8. CNRS, CEA-Institut de Biologie François Jacob, France
  9. Institut Pasteur, CNRS UMR 3523, France

Abstract

Aberrant DNA methylation is a well‑known feature of tumours and has been associated with metastatic melanoma. However, since melanoma cells are highly heterogeneous, it has been challenging to use affected genes to predict tumour aggressiveness, metastatic evolution, and patients' outcomes. We hypothesized that common aggressive hypermethylation signatures should emerge early in tumorigenesis and should be shared in aggressive cells, independent of the physiological context under which this trait arises. We compared paired melanoma cell lines with the following properties: (i) each pair comprises one aggressive counterpart and its parental cell line, and (ii) the aggressive cell lines were each obtained from different host and their environment (human, rat, and mouse), though starting from the same parent cell line. Next, we developed a multi-step genomic pipeline that combines the DNA methylome profile with a chromosome cluster-oriented analysis. A total of 229 differentially hypermethylated genes were commonly found in the aggressive cell lines. Genome localization analysis revealed hypermethylation peaks and clusters, identifying eight hypermethylated gene promoters for validation in tissues from melanoma patients. Five CpG identified in primary melanoma tissues were transformed into a DNA methylation score that can predict survival (Log-rank test, p=0.0008). This strategy is potentially universally applicable to other diseases involving DNA methylation alterations.

Data availability

Sequencing data have been deposited in GEO under accession code GSE155856R-scripts are available in Source Code 1 fileThe datasets supporting the conclusions of this article are included within the article and the following Supplementary files

The following data sets were generated

Article and author information

Author details

  1. Arnaud Carrier

    Unité de Service et de Recherche USR 3388, CNRS-Pierre Fabre, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Cécile Desjobert

    Unité de Service et de Recherche USR 3388, CNRS-Pierre Fabre, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Loic Ponger

    CNRS UMR 7196, INSERM U1154, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Laurence Lamant

    Cancer Research Center of Toulouse, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Matias Bustos

    Department of Translational Molecular Medicine, Providence Saint John's Health Center, Santa Monica, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Jorge Torres-Ferreira

    Cancer Biology and Epigenetics Group, Portuguese Oncology Institute, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  7. Rui Henrique

    Cancer Biology and Epigenetics Group, Portuguese Oncology Institute, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  8. Carmen Jeronimo

    Cancer Biology and Epigenetics Group, Portuguese Oncology Institute, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  9. Luisa Lanfrancone

    Department of Experimental Oncology, Instituto Europeo di Oncologia, Milan, Italy
    Competing interests
    The authors declare that no competing interests exist.
  10. Audrey Delmas

    Cancer Research Center of Toulouse, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Gilles Favre

    Cancer Research Center of Toulouse, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  12. Antoine Delaunay

    Laboratory for Functional Genomics, Fondation Jean Dausset-CEPH, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  13. Florence Busato

    Laboratory for Epigenetics and Environment, CNRS, CEA-Institut de Biologie François Jacob, Evry, France
    Competing interests
    The authors declare that no competing interests exist.
  14. Dave SB Hoon

    Department of Translational Molecular Medicine, Providence Saint John's Health Center, Santa Monica, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Jorg Tost

    Laboratory for Epigenetics and Environment, CNRS, CEA-Institut de Biologie François Jacob, Evry, France
    Competing interests
    The authors declare that no competing interests exist.
  16. Chantal Etievant

    Unité de Service et de Recherche USR 3388, CNRS-Pierre Fabre, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  17. Joëlle Riond

    Unité de Service et de Recherche USR 3388, CNRS-Pierre Fabre, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  18. Paola B Arimondo

    Department Structural Biology and Chemistry, Institut Pasteur, CNRS UMR 3523, Paris, France
    For correspondence
    paola.arimondo@cnrs.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5175-4396

Funding

CNRS (ATIP to PBA)

  • Paola B Arimondo

Region Midi Pyrenees-CNRS (Equipe d'excellence to PBA)

  • Paola B Arimondo

Region Midi Pyrenees - CNRS (FEDER to PBA)

  • Paola B Arimondo

Fondation InnaBioSante (EpAM to PBA)

  • Paola B Arimondo

Adelson Medical Research Foundation (grant to DH and MB)

  • Dave SB Hoon

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Tumour samples from melanoma patients were obtained from the tumour tissue bank at the Department of Pathology, IUCT-O Toulouse Hospital (France). The study was carried out in accordance with the institutional review board-approved protocols (CRB, AC-2013-1955) and the procedures followed were in accordance with the Helsinki Declaration.This study was approved by the institutional ethics committee of IPO Porto (CES-IPOP-FG13/2016).

Reviewing Editor

  1. C Daniela Robles-Espinoza, International Laboratory for Human Genome Research, Mexico

Version history

  1. Received: March 11, 2022
  2. Preprint posted: April 12, 2022 (view preprint)
  3. Accepted: September 18, 2022
  4. Accepted Manuscript published: September 20, 2022 (version 1)
  5. Version of Record published: September 30, 2022 (version 2)

Copyright

© 2022, Carrier et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 440
    Page views
  • 145
    Downloads
  • 1
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Arnaud Carrier
  2. Cécile Desjobert
  3. Loic Ponger
  4. Laurence Lamant
  5. Matias Bustos
  6. Jorge Torres-Ferreira
  7. Rui Henrique
  8. Carmen Jeronimo
  9. Luisa Lanfrancone
  10. Audrey Delmas
  11. Gilles Favre
  12. Antoine Delaunay
  13. Florence Busato
  14. Dave SB Hoon
  15. Jorg Tost
  16. Chantal Etievant
  17. Joëlle Riond
  18. Paola B Arimondo
(2022)
DNA methylome combined with chromosome cluster-oriented analysis provides an early signature for cutaneous melanoma aggressiveness
eLife 11:e78587.
https://doi.org/10.7554/eLife.78587

Further reading

    1. Cancer Biology
    2. Genetics and Genomics
    Ann-Kathrin Herzfeldt, Marta Puig Gamez ... Lee Kim Swee
    Research Article

    Cytotoxic CD8+ T lymphocytes (CTLs) are key players of adaptive anti-tumor immunity based on their ability to specifically recognize and destroy tumor cells. Many cancer immunotherapies rely on unleashing CTL function. However, tumors can evade killing through strategies which are not yet fully elucidated. To provide deeper insight into tumor evasion mechanisms in an antigen-dependent manner, we established a human co-culture system composed of tumor and primary immune cells. Using this system, we systematically investigated intrinsic regulators of tumor resistance by conducting a complementary CRISPR screen approach. By harnessing CRISPR activation (CRISPRa) and CRISPR knockout (KO) technology in parallel, we investigated gene gain-of-function as well as loss-of-function across genes with annotated function in a colon carcinoma cell line. CRISPRa and CRISPR KO screens uncovered 187 and 704 hits respectively, with 60 gene hits overlapping between both. These data confirmed the role of interferon‑γ (IFN-γ), tumor necrosis factor α (TNF-α) and autophagy pathways and uncovered novel genes implicated in tumor resistance to killing. Notably, we discovered that ILKAP encoding the integrin-linked kinase-associated serine/threonine phosphatase 2C, a gene previously unknown to play a role in antigen specific CTL-mediated killing, mediate tumor resistance independently from regulating antigen presentation, IFN-γ or TNF-α responsiveness. Moreover, our work describes the contrasting role of soluble and membrane-bound ICAM-1 in regulating tumor cell killing. The deficiency of membrane-bound ICAM-1 (mICAM-1) or the overexpression of soluble ICAM-1 (sICAM-1) induced resistance to CTL killing, whereas PD-L1 overexpression had no impact. These results highlight the essential role of ICAM-1 at the immunological synapse between tumor and CTL and the antagonist function of sICAM-1.

    1. Cancer Biology
    2. Cell Biology
    Marianne Mazevet, Anissa Belhadef ... Eric Morel
    Research Article Updated

    Anthracyclines, such as doxorubicin (Dox), are widely used chemotherapeutic agents for the treatment of solid tumors and hematologic malignancies. However, they frequently induce cardiotoxicity leading to dilated cardiomyopathy and heart failure. This study sought to investigate the role of the exchange protein directly activated by cAMP (EPAC) in Dox-induced cardiotoxicity and the potential cardioprotective effects of EPAC inhibition. We show that Dox induces DNA damage and cardiomyocyte cell death with apoptotic features. Dox also led to an increase in both cAMP concentration and EPAC1 activity. The pharmacological inhibition of EPAC1 (with CE3F4) but not EPAC2 alleviated the whole Dox-induced pattern of alterations. When administered in vivo, Dox-treated WT mice developed a dilated cardiomyopathy which was totally prevented in EPAC1 knock-out (KO) mice. Moreover, EPAC1 inhibition potentiated Dox-induced cell death in several human cancer cell lines. Thus, EPAC1 inhibition appears as a potential therapeutic strategy to limit Dox-induced cardiomyopathy without interfering with its antitumoral activity.